Rare Intersections: Two Cases Illustrating the Immune Complexity of Chronic Lymphocytic Leukemia Associated With Paraneoplastic Pemphigus With Ocular Involvement and Temozolomide-Induced Autoimmune Cytopenias in Concurrent Lymphoproliferative Disease (SOHO 2026) - Sep 1, 2026 - Abstract #CLL-1401; Location: LEVEL 3, HALL B3; "Despite aggressive multimodal immunosuppression (prednisone, cyclosporine, upadacitinib, intravenous methylprednisolone, IVIG, and cyclophosphamide) alongside venetoclax-obinutuzumab, he achieved near-complete MRD-negative remission but developed fulminant corneal melt with uveal prolapse requiring left eye evisceration. Venetoclax was subsequently discontinued due to severe cytopenias, and therapy was transitioned to acalabrutinib to leverage BTK inhibition for both sustained CLL control and its favorable T-cell immunomodulatory properties relevant to PNP pathogenesis. Escalation with a higher dose of upadacitinib and ruxolitinib is under consideration for refractory mucosal disease...Romiplostim was initiated, with rituximab under consideration for refractory thrombocytopenia... Together, these cases demonstrate that CLL is not a passive bystander but an active immunologic substrate that amplifies the risk of severe paraneoplastic syndromes and unmasks..."
Clinical • Brain Cancer • Chronic Lymphocytic Leukemia • Glioblastoma • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • IGH • MGMT • RUNX1
|
|
Ruben Ruiz Vega MD; Oscar Borja-Montes MD; Omar Bishr MD; Jack Burcher DO; Majed Al-Nazer MD; Muhammad Tariq MD
|